On April 13, 2021, leaders of Mekophar/ MekoStem Company had an online meeting with leaders of CordLab Company and CRC (Singapore). Attending the meeting, from Mekophar and MekoStem, there were: DS Huynh Thi Lan General Director of Mekophar Chemical Pharmaceutical Joint Stock Company, Mrs. Truong Thi Thu Huyen, Acting Director of MekoStem Stem Cell Bank, Dr. Mai Van Dien, Medical Director of MekoStem, Dr. Tran Hoang Ngoc Ai, Laboratory Director of MekoStem. On the Cordlab Company side, there are Professor Ivor Lim, Mr. Gavin Tan, Associate Professor Phan Toan Thang, Mr. Edwin Chow.
At the meeting, the two sides exchanged and informed each other about the work of each side according to the content of cooperation specified in the service contract for storage and technology transfer signed on March 1, 2008. CordLab leaders have announced the company’s successes in research and application of cord membrane stem cells, especially the good news is that CordLab has been licensed by FDA (USA) for culture medium of umbilical cord membrane mesenchymal stem cell. According to Associate Professor Phan Toan Thang so far only CordLab has this copyright from FDA, wich makes the proliferation of mesenchymal stem cells from the umbilical cord membrane more promising in therapeutic applications, because the cell culture medium is one of the top criteria that FDA is concerned about safety in stem cell proliferation process. Taking this opportunity, MekoStem has discussed with CordLab on the cooperation of proliferating mesenchymal stem cells from the umbilical cord membrane with an FDA-approved cell culture medium to meet the needs of a number of MekoStem customers (in Singapore and then in Vietnam).
The Cordlab side also announced the results of clinical research application of mesenchymal cells from umbilical cord membranes to clinical and experimental treatment studies with a number of diseases. This information from Cordlab will be transferred to MekoStem for dissemination on news sites and the Web of MekoStem to serve customers. The MekoStem side informed CordLab about MekoStem’s efforts in developing a new and modern facility in Ho Chi MinhCity High-Tech Park and the Ministry of Health’s appraisal of licensing for the facility’s operation. This is also the fact that MekoStem has passed two international assessments and was granted the Certificate of Accreditation of AABB (American Association of Blood Banks) standards. Both sides agreed to continue to develop cooperation in umbilical cord membrane stem cell technology in the coming time. MekoStem believes that CordLab’s cooperation and support for MekoStem will continue to create favorable opportunities for MekoStem to develop umbilical cord membrane stem cell services in the coming years.
